With 11 days left in their spring session, Illinois lawmakers are reviewing a proposal to establish a state panel. This panel would evaluate prescription drug costs and accessibility. The proposed Prescription Drug Affordability Board is part of a broader Democratic effort aimed at addressing the affordability crisis affecting Illinois and the nation.
Opponents argue that the panel may not effectively lower prices and could add bureaucratic layers to state government. The bill cleared the House Executive Committee, passing 8-4 along party lines, and now awaits a vote by the full House. Supporters view the board as a means to control escalating drug costs, a contentious issue also being tackled at the federal level through recent legislative provisions.
Democratic State Representative Nabeela Syed of Palatine sponsors the bill. She described it as a heavily negotiated package during a committee hearing. The bill was refiled after earlier inaction on the House floor. If established, the board would consist of five members appointed by the governor. It would assess the cost of most prescription drugs, determine whether prices are excessively high, and set upper payment limits, effectively capping consumer expenses.
Pharmaceutical companies could justify their pricing before any cap is imposed. The board would also address medication access, particularly in rural and low-income areas. A significant portion of the legislation ties Illinois drug prices to Medicare’s new negotiating leverage under the 2022 Inflation Reduction Act. Starting this year, Medicare, covering those 65 and older or with disabilities, negotiated lower prices for ten expensive drugs. For instance, the price of Januvia, a diabetes medication, dropped from $527 to $113 for a 30-day supply. Enbrel, for rheumatoid arthritis, decreased from $7,106 to $2,355, as reported by the Centers for Medicare & Medicaid Services.
Under Syed’s bill, these Medicare-negotiated rates would serve as the maximum payment limits for Illinois residents. Medicaid and certain state worker health programs would need to opt in separately. The board would not be able to further reduce prices on drugs already under Medicare’s agreement but could work to ensure these medications reach those in need.
Anusha Thotakura, executive director of Citizen Action/Illinois, supports Syed’s legislation, citing an April study revealing Illinois overpays by more than $190 million for the ten drugs affected by Medicare rates. Despite some disputing this figure, it highlights significant overspending. “In a budget-tight year, people are discussing potential cuts to important services,” she explained. “We seek revenue; however, consider where overspending occurs.”
Board members must demonstrate expertise in healthcare, pharmacy, and clinical medicine. They cannot be employees, board members, or consultants to manufacturers or trade associations. Members serve five-year terms, with initial terms staggered. A 15-member council will aid them, with appointments from the governor, House Speaker, Senate President, and minority leaders. Board decisions may be appealed and subject to judicial review.
The bill includes a provision allowing the Illinois attorney general’s office to enforce board rules. Syed noted any legal shortcomings could be resolved by the Illinois General Assembly. Twelve states have operating Prescription Drug Affordability Boards (PDABs), with some establishing more comprehensive boards than others. States like Colorado, Minnesota, and Maryland have authorized their boards to set upper payment limits.
The Pharmaceutical Research and Manufacturers of America, opposing the Illinois bill, claims active PDABs in other states have not achieved measurable savings. Peter Fotos from PhRMA stated that Medicare’s pricing framework was not designed for state-level application, arguing its structure misaligns with state Medicaid programs, commercial markets, and pharmacy networks.
Deputy Republican leader Ryan Spain of Peoria raised concerns about bureaucracy, noting the absence of a state agency to oversee the board. “If passed, we’d inherit this mess,” he argued, suggesting alignment with a state government entity. Syed testified the board does not need to fall under a specific agency. She estimated operational costs at $750,000. “This board operates independently and is conflict-free,” she commented. A spokesperson for Governor JB Pritzker stated the administration is reviewing the proposal but did not express support for the board.
Meanwhile, the legislature passed another affordability-related bill, backed by Pritzker. The Senate approved a measure targeting “junk fees,” making it illegal to advertise goods or services without mandatory fees included. The bill now awaits Pritzker’s signature.